Jeffrey Adamovicz

Jeffrey Adamovicz

Auto-generated profile, based on publicly available information

Jeffrey Adamovicz

Midwest Research Institute, Frederick, MD USA 21702

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1998 in Vaccine
Verified
Journal Article
Closed access
DHDavid G. Heath
David G. Heath
GAGeorge W. Anderson
George W. Anderson
JMJ.Matthew Mauro
J.Matthew Mauro
SWSusan L. Welkos
Susan L. Welkos
GAGerard P. Andrews
Gerard P. Andrews
AFArthur M. Friedlander
Arthur M. Friedlander

1 February 1994 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SMS C Morris
S C Morris
KMK B Madden
K B Madden
JAJ J Adamovicz
J J Adamovicz
WGW C Gause
W C Gause
BHB R Hubbard
B R Hubbard
FFF D Finkelman
F D Finkelman
The effects of murine rIL-12 on cytokine gene expression and Ig secretion were studied in vivo. In untreated mice IL-12 enhanced IFN-gamma and IL-10 gene expression and protein secretion, reduced base line IL-3 and IL-4 gene expression, and increased serum IgG2a concentration. In mice that had been injected with goat anti-mouse IgD antibody (G alpha M delta) to induce increases in IL-3, IL-4, and IL-10 gene expression and serum IgE, IgG1, IgG2a, and IgG3 concentrations, the simultaneous injection of IL-12 enhanced IFN-gamma and IL-10 gene expression and suppressed IL-3 and IL-4 gene expression and serum IgG and IgE responses. Anti-IFN-gamma mAb neutralized most, but not all, IFN-gamma produced by mice treated with G alpha M delta and IL-12. Anti-IFN-gamma mAb enhanced IL-3 and IL-4 gene expression, did not affect IL-10 or IFN-gamma gene expression, and increased serum IgG1, IgG2a, and IgG3 levels, but had relatively little effect on serum IgE in these mice. In contrast to its effects in G alpha M delta-treated mice, IL-12 failed to inhibit the IgE response to G alpha M epsilon antibody, which stimulates mIgE+ B cells to secrete IgE. These observations demonstrate that: 1) IL-12 may limit its own effects by inducing the production of a cytokine (IL-10) that down-regulates both IL-12 production and IL-12-induced IFN-gamma production; 2) IL-12 inhibits the production of at least one cytokine, IL-3, that is not generally regarded to be strictly Th1- or Th2-associated; 3) IL-12 inhibits switching to IgE secretion to a greater extent than it inhibits switching to other Ig isotypes; and 4) the in vivo effects of IL-12 are, to a large extent, IFN-gamma-dependent.

1 August 2008 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
PAPhilip Arlen
Philip Arlen
MSMichael Singleton
Michael Singleton
JAJeffrey J. Adamovicz
Jeffrey J. Adamovicz
YDYi Ding
Yi Ding
ADAbdolreza Davoodi-Semiromi
Abdolreza Davoodi-Semiromi
HDHenry Daniell
Henry Daniell
The chloroplast bioreactor is an alternative to fermentation-based systems for production of vaccine antigens and biopharmaceuticals. We report here expression of the plague F1-V fusion antigen in chloroplasts. Site-specific transgene integration and homoplasmy were confirmed by PCR and Southern blotting. Mature leaves showed the highest level of transgene expression on the third day of continuous illumination, with a maximum level of 14.8% of the total soluble protein. Swiss Webster mice were primed with adjuvant-containing subcutaneous (s.c.) doses of F1-V and then boosted with either adjuvanted s.c. doses (s.c. F1-V mice) or unadjuvanted oral doses (oral F1-V mice). Oral F1-V mice had higher prechallenge serum immunoglobulin G1 (IgG1) titers than s.c. F1-V mice. The corresponding serum levels of antigen-specific IgG2a and IgA were 2 and 3 orders of magnitude lower, respectively. After vaccination, mice were exposed to an inhaled dose of 1.02 × 106CFU of aerosolizedYersinia pestisCO92 (50% lethal dose, 6.8 × 104CFU). All control animals died within 3 days. F1-V given s.c. (with adjuvant) protected 33% of the immunized mice, while 88% of the oral F1-V mice survived aerosolizedY. pestischallenge. A comparison of splenicY. pestisCFU counts showed that there was a 7- to 10-log reduction in the mean bacterial burden in survivors. Taken together, these data indicate that oral booster doses effectively elicit protective immune responses in vivo. In addition, this is the first report of a plant-derived oral vaccine that protected animals from liveY. pestischallenge, bringing the likelihood of lower-cost vaccines closer to reality.

1 January 2005 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
BPBradford S. Powell
Bradford S. Powell
GAGerard P. Andrews
Gerard P. Andrews
JEJeffrey T. Enama
Jeffrey T. Enama
SJScott Jendrek
Scott Jendrek
CBChris Bolt
Chris Bolt
JAJeffrey J. Adamovicz
Jeffrey J. Adamovicz
A two‐component recombinant fusion protein antigen was re‐engineered and tested as a medical counter measure against the possible biological threat of aerosolized Yersinia pestis. The active component of the proposed subunit vaccine combines the F1 capsular protein and V virulence antigen of Y. pestis and improves upon the design of an earlier histidine‐tagged fusion protein. In the current study, different production strains were screened for suitable expression and a purification process was optimized to isolate an F1‐V fusion protein absent extraneous coding sequences. Soluble F1‐V protein was isolated to 99% purity by sequential liquid chromatography including capture and refolding of urea‐denatured protein via anion exchange, followed by hydrophobic interaction, concentration, and then transfer into buffered saline for direct use after frozen storage. Protein identity and primary structure were verified by mass spectrometry and Edman sequencing, confirming a purified product of 477 amino acids and removal of the N‐terminal methionine. Purity, quality, and higher‐order structure were compared between lots using RP‐HPLC, intrinsic fluorescence, CD spectroscopy, and multi‐angle light scattering spectroscopy, all of which indicated a consistent and properly folded product. As formulated with aluminum hydroxide adjuvant and administered in a single subcutaneous dose, this new F1‐V protein also protected mice from wild‐type and non‐encapsulated Y. pestis challenge strains, modeling prophylaxis against pneumonic and bubonic plague. These findings confirm that the fusion protein architecture provides superior protection over the former licensed product, establish a foundation from which to create a robust production process, and set forth assays for the development of F1‐V as the active pharmaceutical ingredient of the next plague vaccine.

1 May 2007 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
JBJ. Bashaw
J. Bashaw
SNSarah Norris
Sarah Norris
SWS. Weeks
S. Weeks
STS. Trevino
S. Trevino
JAJ. J. Adamovicz
J. J. Adamovicz
SWSusan L. Welkos
Susan L. Welkos
Pneumonic plague is a severe, rapidly progressing disease for which there is no effective vaccine. Since the efficacy of new vaccines cannot be tested in humans, it is essential to develop in vitro surrogate assays that are valid predictors of immunity. The F1 capsule antigen stimulates a protective immune response to most strains ofYersinia pestis. However, strains ofY. pestisthat are F1−but still virulent have been isolated, and an in vitro assay, the results which can predict protection against both F1+and F1−strains, is needed. The virulence antigen (V) is an essential virulence factor ofY. pestisand stimulates protective antibodies. We investigated potential correlates of plague immunity that are based on anti-V antibody-mediated neutralization ofYersinia-induced macrophage cytotoxicity. The neutralizing activity of sera from mice vaccinated with an F1-V fusion candidate vaccine was determined. The decrease in the level of the apoptosis-specific enzyme caspase-3 significantly predicted survival in one- and two-dose vaccination experiments. Sera from F1-V-vaccinated nonhuman primates were evaluated with macrophage assays based on caspase-3 and on other markers manifested at the different stages in cell death. Using murine- and human-derived macrophages in microscopic and fluorescence-activated-cell-sorting-based live/dead staining assays of terminal necrosis, we demonstrated a strong association between in vitro neutralization of macrophage cytotoxicity induced by serum-treatedYersiniaand in vivo protection against lethal infection. These results provide a strong base for the development of reliable in vitro correlate bioassays that are predictive of protective immunity to plague.

1 December 2008 in Vaccine
Verified
Journal Article
Closed access
LKLawrence W. Kummer
Lawrence W. Kummer
FSFrank M. Szaba
Frank M. Szaba
MPMichelle A. Parent
Michelle A. Parent
JAJeffrey J. Adamovicz
Jeffrey J. Adamovicz
JHJim Hill
Jim Hill
SSStephen T. Smiley
Stephen T. Smiley